The effects of high physical activity on pharmacokinetic drug interactions

Research output: Contribution to journalReview article

15 Citations (Scopus)

Abstract

Introduction: With the development of new drugs, it is common practice for drug manufacturers to measure their pharmacokinetic parameters. This testing involves the discovery of the absorption, distribution, metabolic, excretory and toxicological properties of drugs. The testing is usually done in non-stressful conditions at rest, however, this does not necessarily tell the entire picture as there is increasing knowledge about the effects that high levels of physical activity can have on the pharmacokinetics of some medications. Areas covered: This review discusses the alterations that physical activity can have on the absorption, distribution, metabolism and elimination parameters of commonly used medications, and clinical outcomes data are reported when known, demonstrating that an interaction exists between exercise and certain medications. This drug-exercise pharmacokinetic interaction alters the performance of medications especially under conditions where exercise is performed for a long period of time. Particular medications that may be affected are those with a narrow therapeutic dosing range, such as digoxin, theophylline and warfarin. Other important medications include insulin and those administered via a transdermal patch drug delivery system. For this review, a literature search was performed between 1966 and 2010. Expert opinion: Patients and healthcare providers should be aware that exercise can adversely affect the way some medications are intended to work. Patients taking certain medications should be closely monitored when performing high amounts of physical activity.

Original languageEnglish
Pages (from-to)257-266
Number of pages10
JournalExpert Opinion on Drug Metabolism and Toxicology
Volume7
Issue number3
DOIs
StatePublished - Mar 2011

Fingerprint

Drug interactions
Pharmacokinetics
Drug Interactions
Exercise
Pharmaceutical Preparations
Digoxin
Testing
Warfarin
Theophylline
Metabolism
Transdermal Patch
Insulin
Expert Testimony
Drug Delivery Systems
Health Personnel
Toxicology

All Science Journal Classification (ASJC) codes

  • Toxicology
  • Pharmacology

Cite this

The effects of high physical activity on pharmacokinetic drug interactions. / Lenz, Thomas L.

In: Expert Opinion on Drug Metabolism and Toxicology, Vol. 7, No. 3, 03.2011, p. 257-266.

Research output: Contribution to journalReview article

@article{17f7700ebde649e387ec27f518e6a48d,
title = "The effects of high physical activity on pharmacokinetic drug interactions",
abstract = "Introduction: With the development of new drugs, it is common practice for drug manufacturers to measure their pharmacokinetic parameters. This testing involves the discovery of the absorption, distribution, metabolic, excretory and toxicological properties of drugs. The testing is usually done in non-stressful conditions at rest, however, this does not necessarily tell the entire picture as there is increasing knowledge about the effects that high levels of physical activity can have on the pharmacokinetics of some medications. Areas covered: This review discusses the alterations that physical activity can have on the absorption, distribution, metabolism and elimination parameters of commonly used medications, and clinical outcomes data are reported when known, demonstrating that an interaction exists between exercise and certain medications. This drug-exercise pharmacokinetic interaction alters the performance of medications especially under conditions where exercise is performed for a long period of time. Particular medications that may be affected are those with a narrow therapeutic dosing range, such as digoxin, theophylline and warfarin. Other important medications include insulin and those administered via a transdermal patch drug delivery system. For this review, a literature search was performed between 1966 and 2010. Expert opinion: Patients and healthcare providers should be aware that exercise can adversely affect the way some medications are intended to work. Patients taking certain medications should be closely monitored when performing high amounts of physical activity.",
author = "Lenz, {Thomas L.}",
year = "2011",
month = "3",
doi = "10.1517/17425255.2011.553190",
language = "English",
volume = "7",
pages = "257--266",
journal = "Expert Opinion on Drug Metabolism and Toxicology",
issn = "1742-5255",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - The effects of high physical activity on pharmacokinetic drug interactions

AU - Lenz, Thomas L.

PY - 2011/3

Y1 - 2011/3

N2 - Introduction: With the development of new drugs, it is common practice for drug manufacturers to measure their pharmacokinetic parameters. This testing involves the discovery of the absorption, distribution, metabolic, excretory and toxicological properties of drugs. The testing is usually done in non-stressful conditions at rest, however, this does not necessarily tell the entire picture as there is increasing knowledge about the effects that high levels of physical activity can have on the pharmacokinetics of some medications. Areas covered: This review discusses the alterations that physical activity can have on the absorption, distribution, metabolism and elimination parameters of commonly used medications, and clinical outcomes data are reported when known, demonstrating that an interaction exists between exercise and certain medications. This drug-exercise pharmacokinetic interaction alters the performance of medications especially under conditions where exercise is performed for a long period of time. Particular medications that may be affected are those with a narrow therapeutic dosing range, such as digoxin, theophylline and warfarin. Other important medications include insulin and those administered via a transdermal patch drug delivery system. For this review, a literature search was performed between 1966 and 2010. Expert opinion: Patients and healthcare providers should be aware that exercise can adversely affect the way some medications are intended to work. Patients taking certain medications should be closely monitored when performing high amounts of physical activity.

AB - Introduction: With the development of new drugs, it is common practice for drug manufacturers to measure their pharmacokinetic parameters. This testing involves the discovery of the absorption, distribution, metabolic, excretory and toxicological properties of drugs. The testing is usually done in non-stressful conditions at rest, however, this does not necessarily tell the entire picture as there is increasing knowledge about the effects that high levels of physical activity can have on the pharmacokinetics of some medications. Areas covered: This review discusses the alterations that physical activity can have on the absorption, distribution, metabolism and elimination parameters of commonly used medications, and clinical outcomes data are reported when known, demonstrating that an interaction exists between exercise and certain medications. This drug-exercise pharmacokinetic interaction alters the performance of medications especially under conditions where exercise is performed for a long period of time. Particular medications that may be affected are those with a narrow therapeutic dosing range, such as digoxin, theophylline and warfarin. Other important medications include insulin and those administered via a transdermal patch drug delivery system. For this review, a literature search was performed between 1966 and 2010. Expert opinion: Patients and healthcare providers should be aware that exercise can adversely affect the way some medications are intended to work. Patients taking certain medications should be closely monitored when performing high amounts of physical activity.

UR - http://www.scopus.com/inward/record.url?scp=79951927853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951927853&partnerID=8YFLogxK

U2 - 10.1517/17425255.2011.553190

DO - 10.1517/17425255.2011.553190

M3 - Review article

VL - 7

SP - 257

EP - 266

JO - Expert Opinion on Drug Metabolism and Toxicology

JF - Expert Opinion on Drug Metabolism and Toxicology

SN - 1742-5255

IS - 3

ER -